BiotechTube

erlotinib hydrochloride + gemcitabine hydrochloride

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Cancer

Conditions

Pancreatic Cancer

Trial Timeline

Apr 1, 2009 → Jun 15, 2019

NCT ID
NCT00733746

About erlotinib hydrochloride + gemcitabine hydrochloride

erlotinib hydrochloride + gemcitabine hydrochloride is a phase 2 stage product being developed by Astellas Pharma for Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00733746. Target conditions include Pancreatic Cancer.

What happened to similar drugs?

9 of 20 similar drugs in Pancreatic Cancer were approved

Approved (9) Terminated (4) Active (11)
✅DalteparinEisaiApproved
✅CREONAbbVieApproved
✅Pancrelipase + PlaceboAbbVieApproved
✅Pancrelipase CapsulesAbbVieApproved
✅Chromogranin ANovartisApproved
✅Pasireotide + DiazoxideNovartisApproved
✅everolimusNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00733746Phase 2Completed
NCT00033241Phase 1Completed

Competing Products

20 competing products in Pancreatic Cancer

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
pemetrexedEli LillyPhase 2
35
mFOLFIRINOX + RamucirumabEli LillyPhase 2
35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
enzastaurin + gemcitabineEli LillyPhase 2
35
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4Eli LillyPhase 1
29
RamucirumabEli LillyPhase 1/2
32
GEMZAR + ALIMTAEli LillyPhase 3
40
CS-1008 (humanized anti-DR5 antibody) + gemcitabineDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
exatecan mesylate + gemcitabine hydrochlorideDaiichi SankyoPhase 3
40
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
AGS-1C4D4 + gemcitabineAstellas PharmaPhase 2
35
erlotinib + gemcitabine + nab-paclitaxelAstellas PharmaPhase 1
29
erlotinib hydrochloride + gemcitabine hydrochlorideAstellas PharmaPhase 1
29
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
35
Tarceva (erlotinib HCl, OSI-774)Astellas PharmaPhase 3
40